IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 14.960-15.160 for the period, compared to the consensus estimate of 14.860. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Stock Performance

IDXX stock opened at $671.64 on Tuesday. The company has a market cap of $52.91 billion, a P/E ratio of 47.23 and a beta of 1.55. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock’s fifty day moving average price is $536.56 and its 200-day moving average price is $573.88.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the prior year, the business earned $3.22 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 9.9% compared to the same quarter last year. On average, equities analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They issued a “sector weight” rating on the stock. Finally, Jefferies Financial Group cut their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. Eight analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $727.75.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 beat estimates: IDEXX reported adjusted EPS of approximately $3.96–$3.98, above the $3.71 consensus estimate, while revenue rose 9.9% year over year to about $1.21 billion, exceeding expectations of $1.19 billion. IDEXX Laboratories earnings report
• Positive Sentiment: Raised 2026 guidance: The company now expects full-year EPS of $14.96–$15.16, above the $14.86 analyst consensus, and revenue of $4.7–$4.8 billion, with the top end exceeding expectations. IDEXX raises forecast
• Positive Sentiment: Recurring diagnostics remained the growth engine: Diagnostics sales to veterinarians increased about 11%, supporting stronger revenue, earnings and investor expectations for continued execution. Morgan Stanley reiterated its Buy rating and maintained an $805 price target. Morgan Stanley reiterates Buy rating
• Neutral Sentiment: The earnings-driven rally was substantial, leaving IDXX near the upper portion of its recent trading range and potentially increasing the risk of profit-taking despite the improved fundamentals. IDEXX surges on Q3 beat
• Negative Sentiment: Margin and demand caveat: Reports indicated that the higher profit outlook was not primarily driven by stronger testing demand, while the margin outlook softened and veterinary visits remained weak. These factors could limit the durability of the rally. IDEXX sales rise as margin outlook slips

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.